Shots:

• Merck KGaA to utilize Personalis’ cancer immunogenomics platform- ImmunoID NeXT to evaluate novel biomarkers and mechanisms of resistance to cancer therapies
• The collaboration leads to the development of novel biomarker identification- analysis of therapy resistance mechanisms- patient stratification- combination therapy strategy and molecular categorization of cancer indications for enabling precision therapy
• Personalis’ ImmunoID NeXT is an end-to-end solution for the discovery of precision oncology biomarkers via clinical applications.  It combines the pioneering NeXT assay- sophisticated analytical engines- and quality support providing researchers with the immunogenomic data needed to drive the programs

Click here to­ read full press release/ article 

Ref: Business wire | Image: Merck KGaA